Stock Ratings | Cantor Fitzgerald: Quince Therapeutics (QNCX) initial rating is "Overweight," with a price target of $4 and a potential upside of 313.14%.
E. I. du Pont de Nemours and Company DD | 0.00 | |
Taysha Gene Therapies, Inc. TSHA | 0.00 | |
Quince Therapeutics, Inc. QNCX | 0.00 | |
Corbus Pharmaceuticals Holdings Inc CRBP | 0.00 | |
Definium Therapeutics, Inc. DFTX | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Morgan Stanley: Maintaining DuPont's E. I. du Pont de Nemours and Company(DD.US) rating at "Market Weight", while raising the price target from $52 to $156.
BMO Capital: Maintaining its "Outperform" rating on Taysha Gene Therapies ( Taysha Gene Therapies, Inc.(TSHA.US) ), while raising its price target from $10 to $14.
Citizens: Maintaining Taysha Gene Therapies' ( Taysha Gene Therapies, Inc.(TSHA.US) ) rating at "Outperform Market," while raising the price target from $8 to $11.
Cantor Fitzgerald: Initial rating for Quince Therapeutics ( Quince Therapeutics, Inc.(QNCX.US) ) at "overweight", with a price target of $4.
Mizuho: Maintaining its "outperform" rating for Corbus Pharmaceuticals Holdings ( Corbus Pharmaceuticals Holdings Inc(CRBP.US) ), while lowering its price target from $44 to $34.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| E. I. du Pont de Nemours and Company(DD.US) | to lift | $156.0 | $46.67 | 234.26% | Morgan Stanley |
| Taysha Gene Therapies, Inc.(TSHA.US) | to lift | $14.0 | $6.86 | 104.08% | BMO Capital |
| Taysha Gene Therapies, Inc.(TSHA.US) | to lift | $11.0 | $6.86 | 60.35% | Citizens |
| Definium Therapeutics, Inc.(DFTX.US) | to lift | $57.0 | $36.18 | 57.55% | Baird |
| Tapestry(TPR.US) | to lift | $230.0 | $150.53 | 52.79% | UBS |
| Quince Therapeutics, Inc.(QNCX.US) | Initial classification | $4.0 | $0.9682 | 313.14% | Cantor Fitzgerald |
| Corbus Pharmaceuticals Holdings Inc(CRBP.US) | cut | $34.0 | $8.46 | 301.89% | Mizuho |
| Fermi Inc.(FRMI.US) | cut | $17.0 | $8.69 | 95.63% | Stifel |
| Accenture Plc Class A(ACN.US) | cut | $226.0 | $127.01 | 77.94% | Mizuho |
| Celsius Holdings, Inc.(CELH.US) | cut | $48.0 | $28.16 | 70.45% | Morgan Stanley |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
UBS: Maintaining a "buy" rating on American American Airlines Group Inc.(AAL.US) ) stock, while raising the price target from $18 to $21.
Canaccord Genuity maintains its "Buy" rating on AbbVie AbbVie, Inc.(ABBV.US) ), raising its price target from $265 to $273.
B of A Securities: Maintaining its rating on Axcelis Technologies ( Axcelis Technologies, Inc.(ACLS.US) ) at "Underperforming the Market", while raising its price target from $130 to $156.
B of A Securities: Maintaining a "buy" rating on Advanced Energy Industries ( Advanced Energy Industries, Inc.(AEIS.US) ), with an upgrade
First Coverage
RBC Capital: Centene Centene Corporation(CNC.US) ) stock has an initial rating of "in line with industry", with a price target of $70.
Deutsche Bank: Initial rating for DXCM stock at "buy", with a target price of $86.
Cantor Fitzgerald: Initial rating for Factorial Energy ( Factorial Energy Inc. Class A(FAC.US) ) at "overweight", with a target price of $18.
Jefferies: Initial rating on FedEx FedEx Freight Holding Company, Inc.(FDXF.US) ) stock at "buy", with a price target of $200
RBC Capital: Initial rating for GE Healthcare Technologies Inc. ( GE Healthcare Technologies Inc.(GEHC.US) ) at "Outperform," with a price target of $80.
Jefferies: Initial rating for Louisiana-Pacific ( Louisiana-Pacific Corporation(LPX.US) ) at "buy", with a target price of $93.
reduction
Mizuho: Maintaining Accenture's ( Accenture Plc Class A(ACN.US) ) rating at "Outperform Market", while lowering the price target from $280 to $226.
Citigroup: Maintaining a "buy" rating on Ally Financial ( Ally Financial Inc(ALLY.US) ), while lowering its price target from $70 to $58.
Wedbush: Downgraded its rating on Apogee Therapeutics ( Apogee Therapeutics, Inc.(APGE.US) ) to "neutral," while maintaining its price target at $135.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk warning:
Investing involves risk, and securities prices can rise or fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.